↓ Skip to main content

Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis

Overview of attention for article published in BMC Nephrology, April 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)

Mentioned by

blogs
1 blog
twitter
15 tweeters
facebook
1 Facebook page
f1000
1 research highlight platform

Citations

dimensions_citation
100 Dimensions

Readers on

mendeley
94 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis
Published in
BMC Nephrology, April 2015
DOI 10.1186/s12882-015-0047-z
Pubmed ID
Authors

Tahir Kanji, Mandark Gandhi, Catherine M Clase, Robert Yang

Abstract

Hyperuricemia may contribute to renal injury. We do not know whether use of treatments that lower urate reduce the progression of chronic kidney disease (CKD) and cardiovascular disease. We performed a systematic review and meta-analysis of randomized controlled trials to assess the benefits and risks of treatments that lower urate in patients with stages 3-5 CKD. We searched MEDLINE, EMBASE, CENTRAL, Web of Science and trial registers for randomized controlled trials (RCTs) without language restriction. Two authors independently screened articles, assessed risk of bias and extracted data. Data obtained included serum uric acid, serum creatinine or other estimates of glomerular filtration rate, incidence of end-stage renal disease (ESRD), systolic and diastolic blood pressure, proteinuria, cardiovascular disease and adverse events. From the 5497 citations screened, 19 RCTs enrolling 992 participants met our inclusion criteria. Given significant heterogeneity in duration of follow-up and study comparators, only trials greater than 3 months comparing allopurinol and inactive control were meta-analyzed using random effects models. Pooled estimate for eGFR was in favour of allopurinol with a mean difference (MD) of 3.2 ml/min/1.73 m(2), 95% CI 0.16-6.2 ml/min/1.73 m(2), p = 0.039 and this was consistent with results for serum creatinine. Statistically significant reductions in serum uric acid, systolic and diastolic blood pressure were found, favouring allopurinol. There were insufficient data on adverse events, incidence of ESRD and cardiovascular disease for analysis. Adequately powered RCTs are needed to establish whether treatments that lower urate have beneficial renal and cardiovascular effects.

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 1%
Spain 1 1%
Belgium 1 1%
Brazil 1 1%
Unknown 90 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 23%
Student > Postgraduate 13 14%
Student > Master 11 12%
Other 11 12%
Student > Ph. D. Student 6 6%
Other 17 18%
Unknown 14 15%
Readers by discipline Count As %
Medicine and Dentistry 61 65%
Nursing and Health Professions 6 6%
Agricultural and Biological Sciences 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Arts and Humanities 1 1%
Other 7 7%
Unknown 12 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2020.
All research outputs
#1,259,692
of 15,923,805 outputs
Outputs from BMC Nephrology
#75
of 1,739 outputs
Outputs of similar age
#22,743
of 231,356 outputs
Outputs of similar age from BMC Nephrology
#1
of 1 outputs
Altmetric has tracked 15,923,805 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,739 research outputs from this source. They receive a mean Attention Score of 3.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 231,356 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them